Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared a recent article by him and colleagues on X:
“More disappointing news in HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after IMbrave050.”
More posts featuring Mark Yarchoan.